Prof. Li Li 李力
Chief Physician, Professor
Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and treatment of gynecologic tumors, including surgery, chemotherapy, radiotherapy, and basic research.
Dr. Li holds a medical master’s degree from Guangxi Medical University (1987) and a PhD from the University of Edinburgh (2001). Formerly Director and Vice President of Guangxi Medical University Cancer Hospital, Dr. Li currently serves as Director of the Gynecologic Oncology Department and the Medical Science Experiment Center. Dr. Li is a doctoral supervisor and editorial board member for several core journals.
Professional roles
- Standing Committee Member, China Anti-Cancer Association
- Standing Committee Member, Chinese Society of Clinical Oncology (CSCO) Tumor Clinical Collaboration Center
- Vice Chair, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Gynecologic Oncology Group, Chinese Medical Association
Name order: in Chinese the family name comes first (Li Li). Papers usually list the name as Li Li or Li L.
Selected publications
25 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Oncol, 2023 (senior author): High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer. PubMed 36527574
- J Ovarian Res, 2023 (senior author): Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer. PubMed 36823642
- Hum Exp Toxicol, 2023 (senior author): Biological function of C-X-C Motif Chemokine Ligand 1 gene (CXCL1) in ovarian malignant tumors. PubMed 37787042
- Front Oncol, 2022 (senior author): MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients. PubMed 35592674
- BMC Cancer, 2022 (senior author): Observation of the cervical microbiome in the progression of cervical intraepithelial neoplasia. PubMed 35379200
- Int J Gen Med, 2022 (senior author): Development and Validation of Nomograms to Predict Overall Survival Outcomes in Serous Ovarian Cancer Patients with Satisfactory Cytoreductive Surgery and Chemotherapy. PubMed 35023951
- Medicine (Baltimore), 2021 (senior author): A meta-analysis of XRCC1 single nucleotide polymorphism and susceptibility to gynecological malignancies. PubMed 34918657
- Front Oncol, 2021 (senior author): Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma. PubMed 34938651
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion